Skip to main content

Advertisement

Log in

Clinicopathological Features, Recurrence Patterns, and Prognosis of Pancreatic Adenocarcinoma with Normal Serum CA19-9. A Consecutive Series of 154 Cases from a Single Institute

  • Original Article
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Background

Serum levels of CA19-9 correlate with recurrence and survival in patients with pancreatic adenocarcinoma; however, little is known about the features and prognosis of pancreatic adenocarcinoma with normal CA19-9 levels.

Method

Patients with pancreatic adenocarcinoma (n = 806) were split into two groups with normal (≤ 37 U/mL) and elevated (> 37 U/mL) CA19–9. The clinicopathological features, survival, and recurrence patterns were compared between two groups. We also sought to identify factors that best predicted prognosis in pancreatic adenocarcinoma with normal CA19-9 levels, to assist in the selection of the most effective adjuvant treatment.

Results

Pancreatic adenocarcinoma with normal CA19-9 were less likely to have lymph node metastasis, angiolymphatic invasion, intrapancreatic neural invasion, anterior serosal invasion, and invasion of the surrounding tissue/organ (distal bile duct, duodenum, or splenic artery or vein). Following propensity-score matching, pancreatic adenocarcinoma with normal CA19-9 levels (≤ 37 U/ml) were associated with significantly superior overall survival following resection. Moreover, the CA19-9 ≤ 37 U/mL group demonstrated a significantly lower rate of local recurrence (35.57% vs. 52.35%, p = 0.004), distant recurrence (42.95% vs. 60.4%, p = 0.003), and mixed recurrence (5.37% vs. 29.53%, p < 0.000) compared with the CA19–9 > 37 U/mL group. Multivariate analysis suggested that angiolymphatic invasion, lymph node metastases, and tumor size > 3 cm were independent prognostic factors for pancreatic adenocarcinoma with normal CA19-9. Survival analyses suggested that post-op chemoradiotherapy or chemotherapy were associated with more favorable outcomes.

Conclusions

Pancreatic adenocarcinoma with normal pretreatment CA19-9 levels (≤ 37 U/ml) were characterized by better biological characteristics, reduced rates of recurrence, and longer overall survival. Moreover, optimal adjuvant therapy should be performed after surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Amanam I, Chung V. Targeted therapies for pancreatic cancer. Cancers, 2018;10(2):97.

    Article  Google Scholar 

  2. Ellison LF, Wilkins K. An update on cancer survival. Health Rep.2010;21(3):55–60

    PubMed  Google Scholar 

  3. Yeole BB, Kumar AV. Population-based survival from cancers having a poor prognosis in Mumbai (Bombay), India. Asian Pac J Cancer Prev. 2004; 5(2):175–182

    PubMed  Google Scholar 

  4. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genetics 1979; 5:957–71.

    Article  CAS  PubMed  Google Scholar 

  5. Safi F, Beger HG, Bittner R, Buchler M, Krautzberger W. CA19-9 and pancreatic adenocarcinoma. Cancer 1986; 57: 779–83.

    Article  CAS  PubMed  Google Scholar 

  6. Magnani J, Nilsson B, Brockhaus M, et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopenteose II. J Biological Chem 1982; 257:14365–9.

    CAS  Google Scholar 

  7. Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jørgensen J, Wolf H, Orntoft TF. Reference values and biological variation for tumor marker CA19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem. 1999;45(1):54–61.

    CAS  PubMed  Google Scholar 

  8. Kijima H, Kashiwagi H, Dowaki S, Ohtani Y, Tobita K, Matsubayasi H, Ajioka Y, Watanabe H, Tsuchida T, Yamazaki H, Nakamura M, Ueyama Y, Tanaka M, Makuuchi H. Stromal sialyl Le(a) expression is correlated with vascular invasion of human gallbladder adenocarcinoma. Int J Oncol. 2000;17(1):55–60.

    CAS  PubMed  Google Scholar 

  9. Matsumoto S. Cimetidine and survival with colorectal cancer. Lancet. 1995;346(8967):115.

    Article  CAS  PubMed  Google Scholar 

  10. Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumor cells. Br J Cancer. 2002;86(2):161–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Yokoigawa N, Takeuchi N, Toda M, et al. Enhanced production of interleukin 6 in peripheral blood monocytes stimulated with mucins secreted into the bloodstream. Clin Cancer Res. 2005; 11(17):6127–32.

    Article  CAS  PubMed  Google Scholar 

  12. Yokoigawa N, Takeuchi N, Toda M, et al. Overproduction of PGE2 in peripheral blood monocytes of gastrointestinal cancer patients with mucins in their bloodstream. Cancer Lett. 2007; 245(1–2):149–55.

    Article  CAS  PubMed  Google Scholar 

  13. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci. 2004;95(5):377–84.

    Article  CAS  PubMed  Google Scholar 

  14. Honn KV, Tang DG, Crissman JD. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev. 1992;11(3–4):325–51.

    Article  CAS  PubMed  Google Scholar 

  15. Waraya M, Yamashita K, Katagiri H. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol 2009.16(5):1231–1240

    Article  PubMed  Google Scholar 

  16. Smith RA, Bosonnet L, Ghaneh P. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg 2008.25(3):226–232

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by CAMS Innovation Fund for Medical Sciences (CIFMS) grant number 2016-I2M-1-001.

Author information

Authors and Affiliations

Authors

Contributions

Yajie Zhao took part in collecting clinical data, reading literature and writing manuscript. Chengfeng Wang was involved in co-supervision, final editing/critical revisions, interpretation/important intellectual content.

Corresponding author

Correspondence to Chengfeng Wang.

Ethics declarations

This study was approved by the Institutional Ethnic Committee on Scientific Research of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, and informed consent was obtained from all patients in this study.

Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper. And CAMS Innovation Fund did not lead to any conflict of interests regarding the publication of this manuscript.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, Y., Wang, C. Clinicopathological Features, Recurrence Patterns, and Prognosis of Pancreatic Adenocarcinoma with Normal Serum CA19-9. A Consecutive Series of 154 Cases from a Single Institute. J Gastrointest Surg 24, 855–865 (2020). https://doi.org/10.1007/s11605-019-04209-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-019-04209-w

Keywords

Navigation